Fibrosing ILD Biomarkers That Rule Acceleration (FIBRALUNG)

Universidade do Porto

Status: Enrolling

Conditions: Pulmonary Fibrosis; Sarcoidosis

Treatments: Other: Comprehensive clinical assessment and biological samples collection

Study type: Observational

Funder types: Other

Identifiers

NCT05635032

FIBRALUNG

Details and patient eligibility

About

FIBRALUNG is a prospective cohort study with biobank of samples from patients with pulmonary fibrosis, aiming to explore the molecular determinants of different clinical outcomes, acute exacerbations and mortality. We expect to gain deeper insight into fibroproliferative common pathways, particularly between idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis, paving the way for new biomarkers that reflect the progressive phenotype, that eventually will support new targeted therapies.

Other idiopathic interstitial pneumonias, connective tissue disease-related interstitial lung diseases and sarcoidosis patients will be also recruited and their biological samples stored for further analyses.

Enrollment: 150 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients aged between 18-80 years
• People undergoing blood collection, lung biopsy and/or BAL as part of their diagnostic workup
• Willingness to undergo the follow-up protocol evaluations
• Treatment-naïve for disease-modifying drugs
• An HRCT scan performed within the last 12 months showing ≥10% fibrosis extent of the lungs

Exclusion criteria

• People who cannot give informed consent
• Pregnancy

Trial design

150 participants in 3 patient groups

IPF

Description:

Patients with Idiophatic Pulmonary Fibrosis (IPF), serving as a prototype of a progressive fibroproliferative disorder.

Treatment:

Other: Comprehensive clinical assessment and biological samples collection

Progressive Pulmonary Fibrosis (non-IPF)

Description:

Patients with non-IPF interstitial lung diseases, presenting a progressive fibrosing phenotype, or acute exacerbations.

Treatment:

Other: Comprehensive clinical assessment and biological samples collection

Non-Progressive Pulmonary Fibrosis (non-IPF)

Description:

Patients with fibrotic non-IPF interstitial lung diseases that are stable during a minimum follow-up of 24 months.

Treatment:

Other: Comprehensive clinical assessment and biological samples collection